Development of novel cancer vaccine therapy using oncolytic Ad-REIC

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K20093
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Urology
• Research Institution: Okayama University
• Principal Investigator: huang peng 岡山大学, 医歯薬学総合研究科, 助教 (00610841)
• Research Collaborator: KUMON HIROMI 岡山大学, 医歯薬学総合研究科, 特命教授 (30144760) ; NASU YASUTOMO 岡山大学, 医歯薬学総合研究科, 教授 (20237572) ; WATANABE MASAMI 岡山大学, 大学病院, 教授 (70444677) ; UEKI HIDEO 岡山大学, 医学部, 技術専門職員 (90537218)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: 限増殖型アデノウイルスベクター / REIC/DKK-3 / 癌ワクチン / 抗癌免疫活性化

Outline of Final Research Achievements

Reduced expression in immortalized cells (REIC)/Dickkopf 3 (Dkk-3) is a tumor suppressor gene that is downregulated in various cancers.　We recently developed a novel specific replication-selective adenovirus Ad-REIC, to achieve more effective therapeutic outcomes and anti-cancer immune escape. In this study, we assessed the anti-tumor immunity effects of replication-selective adenovirus Ad-REIC, and the mechanism had been verify.

Free Research Field

泌尿器科学